RedHill Biopharma (RDHL) Receivables - Other (2025)

RedHill Biopharma (RDHL) reported Receivables - Other of $3.1 million for Q4 2025.

RedHill Biopharma (RDHL) Receivables - Other (2025) Analysis & Trends

RedHill Biopharma (RDHL) has 1 years of Receivables - Other data on file, last reported at $3.1 million in Q4 2025.

  • Receivables - Other for Q4 2025 came in at $3.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $3.1 million (changed N/A YoY), and the FY2025 annual result was $3.1 million, changed N/A from the prior year.
  • Receivables - Other steadied at $3.1 million in Q4 2025 per RDHL's latest filing.
  • Over five years, Receivables - Other peaked at $3.1 million in Q4 2025 and troughed at $3.1 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn
10 RedHill Biopharma 142.34 Mn 142.34 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 3.14 Mn
Dec 31, 2025 3.14 Mn